231 related articles for article (PubMed ID: 32386071)
1. Impact of granulocyte colony-stimulating factor on FOLFIRINOX-induced neutropenia prevention: A population pharmacokinetic/pharmacodynamic approach.
Macaire P; Paris J; Vincent J; Ghiringhelli F; Bengrine-Lefevre L; Schmitt A
Br J Clin Pharmacol; 2020 Dec; 86(12):2473-2485. PubMed ID: 32386071
[TBL] [Abstract][Full Text] [Related]
2. Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach.
Reda M; Macaire P; Bellio H; Uwer L; Ilie S; Lorgis V; Hennequin A; Ladoire S; Rederstorff E; Fumoleau P; Isambert N; Bonnin N; You B; Freyer G; Desmoulins I; Schmitt A
Cancer Chemother Pharmacol; 2022 Feb; 89(2):197-208. PubMed ID: 34997290
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Prophylactic G-CSF in Patients Receiving FOLFIRINOX: A Preliminary Retrospective Study.
Terazawa T; Goto M; Miyamoto T; Asaishi K; Shimamoto F; Kuwakado S; Nishitani H; Kii T; Higuchi K
Intern Med; 2015; 54(23):2969-73. PubMed ID: 26631878
[TBL] [Abstract][Full Text] [Related]
4. Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
Kim G; Cockrum P; Surinach A; Wang S; Wainberg Z
Curr Med Res Opin; 2022 Aug; 38(8):1295-1303. PubMed ID: 35354375
[TBL] [Abstract][Full Text] [Related]
5. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.
Mayordomo JI; Rivera F; Díaz-Puente MT; Lianes P; Colomer R; López-Brea M; López E; Paz-Ares L; Hitt R; García-Ribas I
J Natl Cancer Inst; 1995 Jun; 87(11):803-8. PubMed ID: 7540696
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].
Shi YK; He XH; Yang S; Wang HQ; Jiang ZF; Zhu YZ; Ke XY; Zhang Y; Liu YP; Zhang WJ; Wang Z; Shi QZ; Xie XD; Zhang HL; Wang JJ; Luo DY; Zheng QS; Sun RY
Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(48):3414-9. PubMed ID: 17313855
[TBL] [Abstract][Full Text] [Related]
7. [A Pancreatic Cancer Patient in Whom Pegfilgrastim Prophylaxis Did Not Prevent Severe Neutropenia Caused by the FOLFIRINOX Regimen].
Kiba T; Saito Y; Otomo C; Sato M; Meguro T
Gan To Kagaku Ryoho; 2016 Jul; 43(7):913-5. PubMed ID: 27431641
[TBL] [Abstract][Full Text] [Related]
8. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
[TBL] [Abstract][Full Text] [Related]
9. Eflapegrastim, a Long-Acting Granulocyte-Colony Stimulating Factor for the Management of Chemotherapy-Induced Neutropenia: Results of a Phase III Trial.
Schwartzberg LS; Bhat G; Peguero J; Agajanian R; Bharadwaj JS; Restrepo A; Hlalah O; Mehmi I; Chawla S; Hasal SJ; Yang Z; Cobb PW
Oncologist; 2020 Aug; 25(8):e1233-e1241. PubMed ID: 32476162
[TBL] [Abstract][Full Text] [Related]
10. G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans.
Cardot-Ruffino V; Bollenrucher N; Delius L; Wang SJ; Brais LK; Remland J; Keheler CE; Sullivan KM; Abrams TA; Biller LH; Enzinger PC; McCleary NJ; Patel AK; Rubinson DA; Schlechter B; Slater S; Yurgelun MB; Cleary JM; Perez K; Dougan M; Ng K; Wolpin BM; Singh H; Dougan SK
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344102
[TBL] [Abstract][Full Text] [Related]
11. [Two cases of pancreatic cancer treated with FOLFIRINOX regimen and G-CSF prophylaxis at the standard therapeutic dose].
Kiba T; Okada Y; Kajiume S; Yamaguchi A
Gan To Kagaku Ryoho; 2015 May; 42(5):629-32. PubMed ID: 25981661
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
Yang S; Shi YK; Liu P; Han XH; He XH; Cai YM; Chen ZM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):339-44. PubMed ID: 16900629
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy.
Lane SW; Crawford J; Kenealy M; Cull G; Seymour JF; Prince HM; Marlton P; Gill D; Mollee PN
Leuk Lymphoma; 2006 Sep; 47(9):1813-7. PubMed ID: 17064993
[TBL] [Abstract][Full Text] [Related]
15. Biological and clinical correlates after chemotherapy and granulocyte colony-stimulating factor administration.
Higa GM; DeVore RF; Auber ML; Lynch JP; Landreth KS
Pharmacotherapy; 1998; 18(1):1-8. PubMed ID: 9469674
[TBL] [Abstract][Full Text] [Related]
16. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
Crawford J; Ozer H; Stoller R; Johnson D; Lyman G; Tabbara I; Kris M; Grous J; Picozzi V; Rausch G
N Engl J Med; 1991 Jul; 325(3):164-70. PubMed ID: 1711156
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study.
Kitagawa Y; Osumi H; Shinozaki E; Ota Y; Nakayama I; Suzuki T; Wakatsuki T; Ogura M; Ooki A; Takahari D; Suenaga M; Chin K; Yamaguchi K
BMC Cancer; 2020 Apr; 20(1):358. PubMed ID: 32345249
[TBL] [Abstract][Full Text] [Related]
18. Granulocyte colony-stimulating factor (G-CSF) prevents dose-limiting neutropenia in lymphoma patients receiving standard dose chemotherapy.
Dotti G; Stella CC; Mangoni L; Cottafavi L; Caramatti C; Almici C; Rizzoli V
Haematologica; 1995; 80(2):142-5. PubMed ID: 7543069
[TBL] [Abstract][Full Text] [Related]
19. Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain--results of the LEARN Study.
Almenar D; Mayans J; Juan O; Bueno JM; Lopez JI; Frau A; Guinot M; Cerezuela P; Buscalla EG; Gasquet JA; Sanchez J
Eur J Cancer Care (Engl); 2009 May; 18(3):280-6. PubMed ID: 19076208
[TBL] [Abstract][Full Text] [Related]
20. EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer.
Repetto L; Biganzoli L; Koehne CH; Luebbe AS; Soubeyran P; Tjan-Heijnen VC; Aapro MS
Eur J Cancer; 2003 Nov; 39(16):2264-72. PubMed ID: 14556916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]